Omalizumab in an allergology clinic: Real life experience and future developments

Postepy Dermatologii i Alergologii

Volumn 31, Issue 1, 2014, Pages 32-35

  Kupczyk, Maciej ^a   Kuna, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Allergic asthma; Immunoglobulin E; Omalizumab; Urticaria

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; OMALIZUMAB;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ASTHMA; DRUG EFFICACY; HOSPITAL; HUMAN; IMMUNOLOGY; PERSONAL EXPERIENCE; PRACTICE GUIDELINE; REVIEW; SYSTEMIC ACQUIRED RESISTANCE; TREATMENT DURATION; URTICARIA;

EID: 84896748604     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: 10.5114/pdia.2014.40657     Document Type: Review

References (21)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention updated 2012. Available online at http://www.ginasthma.com
2. Rodrigo GJ, Nefen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139: 28-35.
3. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; 2: CD003559.
4. Braunstahl GJ, Chen CW, Maykut R, et al. The eXpeRience registry: the real-world effectiveness of omalizumab in allergic asthma. Resp Med 3013; 107: 1141-51.
5. Braunstahl GJ, Chlumsky J, Peachey G, Chen CW. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol 2013; 9: 47.
6. Babu KS, Polosa R, Morjaria JB. Anti-IgE - emergin opportunities for omalizumab. Expert Opin Biol Ther 2013; 13: 765-77.
7. Thomson NC, Chaudhuri R. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med 2012; 6: 27-40.
8. Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012; 129: 983-9.
9. Long AA, Fish JE, Rahamaoui A, et al. Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol 2009; 103: 312-9.
10. Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010; 65: 1141-8.
11. Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007; 62: 149-53. (Pubitemid 46090296)
12. Kuprys-Lipinska I, Kuna P. Loss of asthma control after cessation of omalizumab treatment: real life data. Postep Derm Alergol 2014; 31: 1-5.
13. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132: 101-9.
14. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab in the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368: 924-35.
15. Nopp A, Johansson SG, Adedoyin J, et al. After 6 years with Xolair: a 3-year withdrawal follow-up. Allergy 2010; 65: 56-60.
16. Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma: PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol 2011; 72: 306-20.
17. Molimard M, Le Gros V, Bourdeix I, et al. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. European Respiratory Society 2013 Congress. Abstract No. 4693. Abstract book 856s.
18. Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol 2012; 12: 406-11.
19. Kuprys-Lipinska I, Korczynska P, Tworek D, Kuna P. Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust. Postep Derm Alergol 2014; 31: 39-44.
20. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128: 567-73.
21. Maurer M, Magerl M, Metz M, Zuberbier T. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Germ Soc Dermatol 2013 in press. DOI: 10.1111/ddg.12194.